文献速递核素与放射性配体治疗骨显像与常规 SPECT放射性药物与辐射防护

多周期177Lu-DOTA-IBA治疗骨转移的长期安全性与累积疗效:回顾性队列研究

Long-term Safety and Cumulative Efficacy of Multicycle 177 Lu-DOTA-IBA Therapy in Bone Metastases: A Retrospective Cohort Study.
PubMed 文献 · Clin Nucl Med · 2026-06-05

结果显示最佳总体疼痛缓解率(NRS降低≥50%)为88.5%,KPS改善率79.6%,治疗相关骨髓抑制发生率14.3%、肾毒性7.1%,随治疗周期增加未增加血液学或肾毒性风险。

要点

  • 完成≥4周期177Lu-DOTA-IBA治疗的患者中,最佳疼痛缓解率达88.5%,KPS改善率79.6%。
  • 任何级别骨髓抑制发生率为14.3%,肾毒性为7.1%,3级血小板减少为1.8%。
  • 增加治疗周期未伴随血液学或肾毒性的累积风险增加。

核心结论

  • 对于可耐受多周期治疗的骨转移患者,长期177Lu-DOTA-IBA治疗可带来累积症状改善,且累积毒性风险无显著增加,支持其作为长期治疗策略。

主要发现

  • 最佳总体疼痛缓解率(NRS降低≥50%)为88.5%,KPS改善见于79.6%的患者;纵向分析显示跨周期NRS持续降低和KPS持续改善的累积治疗获益。
  • 治疗相关任何级别骨髓抑制8例(14.3%),肾毒性4例(7.1%),3级血小板减少1例(1.8%);未观察到其他3-4级不良事件。
  • 增加治疗周期与血液学或肾毒性增加无关;治疗期间疾病进展独立预测较短生存。

临床怎么用

  • 对于能耐受多周期治疗的骨转移患者,可考虑长期177Lu-DOTA-IBA治疗以累积改善症状,但需监测疾病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the long-term efficacy, safety, and survival outcomes of at least 4 treatment cycles of 177 Lu-DOTA-IBA therapy in patients with bone metastases. PATIENTS AND METHODS: This single-center retrospective cohort study enrolled patients with bone metastases who initiated therapy between November 2021 and May 2024 and completed ≥4 cycles of 177 Lu-DOTA-IBA. The primary endpoints were symptom improvement [Numerical Rating Scale (NRS) and Karnofsky Performance Status (KPS)], safety (Common Terminology Criteria for Adverse Events v5.0), and overall survival. Longitudinal efficacy changes were analyzed using linear mixed-effects models. RESULTS: Fifty-six patients were included: 31 completed 4-5 cycles and 25 completed 6-10 cycles. Pharmacokinetic analysis (n=20) demonstrated a longer effective half-life in lesions than in the whole body, with progressively increasing target-to-nontarget uptake ratios over time. Treatment-related myelosuppression of any grade occurred in 8 patients (14.3%), renal toxicity in 4 (7.1%), and grade 3 thrombocytopenia in 1 (1.8%); no other grade 3-4 adverse events were observed. Increasing treatment cycles were not associated with increased hematological or renal toxicity. The best overall pain response rate (NRS reduction ≥50%) was 88.5%, and KPS improvement was observed in 79.6% of patients. Longitudinal analysis demonstrated cumulative therapeutic benefit, with continuous NRS reduction and KPS improvement across cycles. Disease progression during treatment independently predicted shorter survival. CONCLUSIONS: For patients with bone metastases who can tolerate multicycle therapy, long-term 177 Lu-DOTA-IBA treatment yields cumulative symptom improvement with no significant increase in cumulative toxicity risk, supporting its use as a long-term therapeutic strategy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xu T, Cheng K, Wang P, et al. Long-term Safety and Cumulative Efficacy of Multicycle 177 Lu-DOTA-IBA Therapy in Bone Metastases: A Retrospective Cohort Study. Clin Nucl Med. 2026. PMID: 42257553. doi:10.1097/RLU.0000000000006570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。